A phase II trial presented at the 2021 annual meeting of the American Society of Hematology (ASH) suggested that a novel targeted agent, eprenetapopt (APR-246, a small molecule p53 stabilizer), in combination with AZA as maintenance therapy for TP53-mutated AML or MDS after allo-HSCT was relatively favorable and well tolerated (56). Here, TP53 is linked to myelodysplastic syndrome.